Gadolinium-enhancement depicts BBB disruption associated with new inflammatory MRI lesions in MS and is widely used for diagnosis and therapeutic monitoring. However, earlier and more specific markers of inflammation are urgently needed.
INTRODUCTION
Multiple sclerosis (MS) is a complex immune-mediated disorder of the brain and spinal cord characterized by neuroinflammation, demyelination, gliosis, axonal degeneration and neuronal loss.
During the past decades imaging techniques such as magnetic resonance imaging (MRI) have contributed considerably to the improvement of clinical decision making and the design of clinical trials in multiple sclerosis. Additionally, a range of novel tools using advanced MRI or positron emission tomography (PET) technologies have been emerging from which we can obtain unique insights into pathogenesis of MS. The present article will summarize current developments in MRI and PET techniques to depict neuroinflammation in MS.
MAGNETIC RESONANCE IMAGING
Conventional MRI techniques, such as T2-and T1-weighted sequences, are generally used in the diagnosis, follow-up and therapeutic consideration in individual MS patients and clinical trials.
Currently the most commonly used MRI marker for acute inflammation is gadolinium enhancing white matter lesions (WML), indicating disrupted blood-brain barrier (BBB) in these active MS lesions. Gadolinium-based contrast agents (GBCA) are generally considered safe in patients without severe renal insufficiency, but there is a potential risk for anaphylactoid-type reactions.
[1] Moreover, recent studies suggest accumulation of (potentially toxic) gadolinium may occur in brain tissue in the absence of any significant renal dysfunction.[2*, 3, 4] Apart from the potential side effects of GBCA, the correlation between conventional MRI markers for neuroinflammation and the clinical manifestations of MS in an individual patient is modest. Histopathological studies have shown that (inflammatory) brain pathology in MS is much more diverse and widespread than identified with conventional MRI techniques alone. Various developments regarding in vivo MR imaging have advanced our understanding of the pleomorphic aspects of neuroinflammation in MS in recent years.
SUSCEPTIBILITY WEIGHTED IMAGES
The magnetic property of brain tissue is largely determined by the presence of paramagnetic iron, oxygen levels of the blood in capillaries and veins and the amount of diamagnetic myelin and tissue water. Susceptibility Weighted Images (SWI) uses the differences in magnetic susceptibility in brain tissue to identify MS-related tissue changes such as iron deposition, myelin density and venous capillary network density. To provide a quantitative measure for susceptibility Quantitative Susceptibility Mapping (QSM) was developed. However, these techniques cannot disentangle the different and sometimes opposing factors that increase or decrease tissue susceptibility. [5] Considering the pathophysiology of neuroinflammatory lesions in MS, one of the most striking results from SWI studies is the identification of the central vein in lesions development. Such a central vein has been demonstrated in both periventricular and subcortical MS lesions and is significantly less frequent in non-MS WMLs. [6] [7] [8] Dynamic susceptibility contrast-enhanced (DSC) MRI measures cerebral blood volume and flow by monitoring the first pass of a bolus of GBCA by a series of T2*-weighted MRI images. Regional decreased in blood volume (CBV) and flow (CBF) have been reported in different stages of MS. [14,15*,16] In contrast to the previous two methods, arterial spin labeling (ASL) is a non-invasive perfusion technique that uses magnetization of blood as an endogenous contrast agent.[17*, 18, 19] In an ASL study using multiple delay times, an increase in bolus arrival time (BAT) was demonstrated, indicating reduced perfusion. This is suggested to be caused by widespread arteriolar vasodilation 
LEPTOMENINGEAL ENHANCEMENT
Besides the parenchymal GBCA enhancement used in the diagnoses and therapeutic decision making in MS, leptomeningeal enhancement has been described as part of the pathophysiology of MS ( Figure 1 ). [20] Similar to the process in lesions, gadolinium enhancement of the leptomeninges is a result of vascular leakage and an indirect measure of leptomeningeal inflammation. Traditionally leptomeningeal enhancement is considered suggestive of diagnoses other than MS (e.g. sarcoid), but pathological studies have associated such leptomeningeal inflammation with subpial cortical demyelination and neurodegeneration in both early and late phases of MS. [21, 22] In the last year, two MRI studies have aimed to quantify the prevalence and distribution of leptomeningeal 
ULTRASMALL SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE
As mentioned before, gadolinium-enhancement indicates a defective BBB and is therefore an indirect measure of neuroinflammation in MS. In these lesions infiltrating blood-born monocytes play a crucial role, causing myelin breakdown and phagocytosing myelin debris. The phagocytic infiltration in the CNS can be directly detected in vivo with the use of Ultra-small Superparamagnetic Particles of Iron Oxide (USPIO) as an MRI contrast agent. Several hours after intravenous administration of USPIO these small nanoparticles are captured by phagocytic monocytes and accumulate in these cells. [25] Their iron oxide core distorts the magnetic field, causing a rapid decreases in T1-and T2-relaxation times of water molecules, resulting in an increased signal intensity on T1-weighted images and a decrease of signal on T2-weighted-gradient echo images. [25, 26] Areas of altered intensity on delayed MRI scans presumably reflect the infiltration of USPIO-loaded macrophages in active MS lesions.
USPIO enhancement can have one of three patterns: focal, ring-like or "return-to-isointensity" (after having been hypointense on native T1-weighted images). [27] Furthermore, global changes in the T1 signal in normal appearing brain tissue can demonstrate subtle generalized inflammatory activity without apparent BBB damage. [28] Clinical pilot trials have demonstrated that the use of both GBCA and USPIO in MS patients identifies more inflammatory lesions than gadolinium alone, range from a 4% to 244% increase. [27, 29, 30] The subgroup of lesions that enhanced with both contrast agents were characterized by a more severe evolution. [27, 30] A recent study by Maarouf 
POSITRON EMISSION TOMOGRAPHY
PET is a noninvasive molecular imaging technique to quantify biochemical and physiological processes in vivo. It measures the bio-distribution of a radioligand or tracer, a radioactive isotope bound to biologically active molecule. Over the last decades more and more new radioligands have been developed, creating a unique insight in the pathophysiology of neuroinflammation, neuronal dysfunction, demyelination and remyelination. In this review we will focus on PET-tracers as biomarkers for neuroinflammation.
IMAGING ACTIVATED MICROGLIA
The complex and highly dynamic processes of microglia activation is the central characteristic of neuroinflammation and a key element of neurodegeneration in MS. [32, 33] Initially, in vivo PETstudies investigating microglia activation used radioligands that bind to the 18kd-translocator protein (TSPO), formerly known as peripheral benzodiazepine receptor. The first successful and now most frequently used of the TSPO-radioligands is [ 11 C]PK11195. [34] [ 11 C]PK11195 uptake is increased in focal T2 MRI lesions, co-localizes with gadolinium-enhancing T1 lesions in RRMS and is increased in normal appearing white and grey matter (NAWM and NAGM) in MS patients compared to healthy controls. [35] [36] [37] Overall there is significant positive correlation with [ 11 C]PK11195 uptake and disease duration, disability score and brain atrophy. [35] [36] [37] [38] However, [ 11 C]PK11195 has several disadvantages, including limited brain entrance, poor signal-to-noise ratio and labeling with the impractically rapid decaying isotope [ 11 C] (t1/2 = 20.33 minutes). [39] This led to the development of a wide range of second generation TSPO radioligands, see table 1 for an overview of TSPO PET-studies in MS patients. The main disadvantage of these new tracers is a single nucleotide polymorphisms in the TSPO gene (rs697) that induces a variation in binding activity for these second generation TSPO tracers. [50] Differences in affinity between the high-affinity binding type and the low-affinity binding type varies between the different TSPO tracers from a 4-fold to as high as a 50-fold decrease in binding. [50] Besides the use of different tracers and genetic polymorphism, comparison of TSPO PET studies can be challenging due to differences in quantification methods of specific binding, as well as differences in patient population, such as subtypes of MS, disease duration, disease severity and age. Recent Overall, increase in TSPO uptake appears to be related to disease severity and progression.
NOVEL PET-TRACERS FOR ACTIVATED MICROGLIA
Besides TSPO radioligands, new PET-tracers with different binding targets on microglia are under development.
In MS the purinergic, adenosine triphosphate (ATP) binding, receptor P2X7 (P2X7R) is upregulated on microglia. Binding of ATP to the receptor activates the microglia, which leads to proliferation and release of the pro-inflammatory cytokine and subsequently microglia recruitment. [54] Recently, ATPdependent release of tumor necrosis factor α (TNFα) was demonstrated to have a neuroprotective effect in MS. [55] Moreover, a rare single nucleotide polymorphism rs28360457 in the P2X7R gene has been described to protect against the risk of developing MS. To quantify the brain penetration of siponimod (BAF312), a selective sphingosine-1-phosphate receptor (S1PR) agonist in phase 3 development for treatment of SPMS, Briard et al. developed compound MS565. [63, 64] By slightly modifying the structure of BAF312 this molecule can be labelled to [ 124 I] for PET imaging. Despite the additional iodine atom the biochemical properties and pharmacokinetics of[ 124 I]MS565 remain very close to the original compound. In a similar fashion they previously developed [ 124 I]BZM055 as a surrogate tracer to study the biodistribution of fingolimod (FTY720), a S1PR agonist approved for the treatment of RRMS. [65] Further validation of these radioligands is necessary.
In contrast to radioligands based on MS specific small molecules, radioactive labelling of monoclonal antibodies (mAbs) has already been validated in oncology. [66] Table) Tabel 
